^
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive
:
A1
TP53 wild-type
Small Lymphocytic Lymphoma
PCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
FCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2